The drugmakers’ shares were down by 18 percent on six times the normal trading volume, which prompted the company to release a statement saying it doesn’t have information that would explain the drop.
On Sept. 13, Catalyst’s stocks fell 17 percent after announcing plans to sell 8 million shares to generate capital to buy or license other medicines.
Last year, the drugmaker came under fire after it received orphan status for its $375,000 drug, Firdapse, which made a free alternative unavailable to patients.
More articles on pharmacy:
World Pharmacist Day promotes use of safe and effective medicines
USP delays release of updated compounding standards
Americans pay up to 67 times more for drugs than other countries
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
